e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
From rare towards common lung diseases: diagnostic and monitoring challenges
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum and urine Clara cell 16-kDa protein in community-acquired pneumonia patients
L. Andersson, K. Strålin, L. Barregård (Gothenburg, Örebro, Sweden)
Source:
Annual Congress 2010 - From rare towards common lung diseases: diagnostic and monitoring challenges
Session:
From rare towards common lung diseases: diagnostic and monitoring challenges
Session type:
Thematic Poster Session
Number:
4620
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Andersson, K. Strålin, L. Barregård (Gothenburg, Örebro, Sweden). Serum and urine Clara cell 16-kDa protein in community-acquired pneumonia patients. Eur Respir J 2010; 36: Suppl. 54, 4620
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006
Serum levels of IL-6 in severe community-acquired pneumonia
Source: Annual Congress 2010 - Pulmonary infections and sepsis
Year: 2010
Measurements usefulness of serum C-reactive protein for management of adult community-acquired pneumonia
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
C-reactive protein in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Serum procalcitonin and community-acquired pneumonia in childhood
Source: Eur Respir J 2005; 26: Suppl. 49, 167s
Year: 2005
C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005
Clara cell secretory protein and its mRNA expression in induced sputum of acute bacterial exacerbations of COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 543s
Year: 2002
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Source: Eur Respir J 2008; 32: 726-732
Year: 2008
Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia
Source: Eur Respir J 2005; 25: 688-692
Year: 2005
C-reactive protein levels in community-acquired pneumonia
Source: Eur Respir J 2003; 21: 702-705
Year: 2003
Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP)
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016
Clara cell protein (CC16) in serum and urine after exercise challenge
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012
Serum KL-6 level is increased in patients with
pneumocystis
pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 101s
Year: 2006
Serum procalcitonin in pneumococcal pneumonia in children
Source: Eur Respir J 2001; 17: 623-627
Year: 2001
Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis
Source: Annual Congress 2009 - Biomarkers and biology in COPD
Year: 2009
Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Serum procalcitonin concentrations in children with pulmonary tuberculosis, tuberculous infection and lober pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 176s
Year: 2003
The influence of prednisolone on C-reactive protein and procalcitonin in patients hospitalised with community-acquired pneumonia
Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Year: 2010
Clara cell secretory protein (CC16) and surfactant protein D (SPD) in sputum supernatant in severe refractory asthma (SRA)
Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept